Efficacy

For adults with triple-negative breast cancer (TNBC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery and who have received two or more prior treatments, including at least one treatment for metastatic disease

In a phase 3 study, TRODELVY WAS PROVEN TO BE MORE EFFECTIVE at slowing disease progression THAN TRADITIONAL CHEMOTHERAPIES

TRODELVY was studied in a large phase 3 study in adults with TNBC that had spread to other parts of the body (metastatic) or could not be removed by surgery and who had previously received 2 or more therapies for breast cancer, at least one of them for metastatic disease

Graphic showing that 33.3% of patients saw their tumors shrink

TRODELVY delayed the spread of mTNBC

In the clinical trial, some patients taking TRODELVY showed no signs of mTNBC getting worse for 4.8 months vs 1.7 months for patients taking traditional chemotherapies. This is also called “median Progression-Free Survival (PFS),” which is how long a treatment stops the growth or spread of mTNBC in half the people who take it.

Patients taking TRODELVY lived longer than those taking traditional chemotherapies

In the clinical trial, TRODELVY helped patients live nearly 2x longer than patients who were taking traditional chemotherapies. This is also called “median Overall Survival (OS),” which is how long half of patients were alive after starting treatment.

Graphic showing that 33.3% of patients saw their tumors shrink

Results shown are in all patients (with and without brain cancer).
TRODELVY may not work for everyone. Individual results may vary.